Pathos AI closes $237M and partners with Bristol Myers, Tempus

Large AI-drug-development round shows continued investor appetite in AI biotech.

AI drug development startup Pathos AI closed a $237M investment and is teaming up with Bristol Myers Squibb and Tempus AI to advance drug development.

Domain

health

Read it at CNA →

Coverage: 3 sources, in order

1. 23 Oct 13:00 CNA Read the article →
2. 23 Oct 13:19 The Economic Times Read the article →
3. 23 Oct 20:02 SiliconANGLE Read the article →

← Front page